Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has received an average rating of “Moderate Buy” from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price objective […]
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average […]
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) is set to post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect Travere Therapeutics to post earnings of ($0.98) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link. Travere Therapeutics (NASDAQ:TVTX […]
A single-center assessment showed patients with glomerulonephritis may face a heightened risk of primary disease recurrence up to 1 year after transplant.